AzTrials
AzTrials

Postpartum HemorrhagePhase 4NCT03676621

Buccal Misoprostol Versus IV Oxytocin in Prevention of Postpartum Hemorrhage

A Phase 4 study testing Misoprostol and Oxytocin in people with Postpartum Hemorrhage, run by Assiut University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Cesarean delivery is defined as fetal birth through incisions in the abdominal wall and the uterine wall (hysterotomy). This definition does not include removal of the fetus from the abdominal cavity in the case of uterine rupture or in the case of an abdominal pregnancy Read more about this study

Who is it for?
Ages 18 to 40 years, women only
Conditions the study is for
Postpartum Hemorrhage
What is being tested?
Misoprostol and Oxytocin
Could I receive a placebo?
No, everyone receives an active treatment
How many people
154 participants
Where
1 siteEgypt
Study dates
1 Nov 2018to 20 Sep 2021
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • pregnant women
  • term pregnancy
  • singleton pregnancies
  • booked for elective cesarean section

Who cannot join

  • • Medical disorders involving the heart,liver,kidney or brain
  • Diabetes mellitus and hypertension
  • Blood disorders (e.g. coagulopathies , thrombocytopenia )
  • Patients requiring blood transfusion due to anemia
  • Risk factors for uterine atony e.g. macrosomia , polyhydramnios ,multiple pregnancies
  • Placenta previa or placental abruption
Show all 11Show fewer
  • Previous major obstetric haemorrhage (>1000ml)in previous deliveries
  • Known fibroid or adenomyosis
  • Severe preeclampsia
  • Uterine anomalies
  • Women who received anticoagulant therapy

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Assiut Faculty of Medicine

    Asyut

Other trials in Egypt

About this study

Official title: Buccal Misoprostol Versus IV Oxytocin in Prevention of Postpartum Hemorrhage :a Randomized Controlled Study

Cesarean delivery is defined as fetal birth through incisions in the abdominal wall and the uterine wall (hysterotomy). This definition does not include removal of the fetus from the abdominal cavity in the case of uterine rupture or in the case of an abdominal pregnancy

Read the detailed description

patients and methods:

Type of Study

A prospective registered, double blinded, randomized controlled trial

Settings and localizations:

Operative list and emergency unit at Obstetrics and Gynecology Department, Women Health Hospital, Assiut university, Egypt

Preliminary assessment of the patient

Obtain a detailed history from the patient

  • Examination of the patient
  1. General examination and evaluation of the vital signs ofthe patient ( pulse , blood pressure , temperature and respiratory rate)
  2. Obstetrical examination Ultrasonograghic assessment (fetal viability , number of gestation, placental location, amniotic fluid index) Investigations ( complete blood count, Prothrombin time and concentration). Inclusion criteria: All legally adult pregnant women , above 18 years old ,at term with singleton pregnancies booked for elective caesarean section accepting to participate in the study. Indications of cesarean section: Repeated caesarean section(previous 2 cs or more). previous one caesarean with oligohydramnios. previous one caesarean with contracted pelvis. previous one caesarean with malpresentation. previous one caesarean section with decreased fetal movement. primigravida with malpresentation. primigravida with contracted pelvis. Exclusion criteria: Medical disorders involving the heart,liver,kidney or brain. Diabetes mellitus and hypertension. Patients requiring blood transfusion due to anemia. Risk factors for uterine atony e.g. macrosomia , polyhydramnios ,multiple pregnancies. Placenta previa or placental abruption. Previous major obstetric haemorrhage (>1000ml in previous Deliveries). Known fibroid or adenomyosis. Severe preeclampsia. Uterine anomalies. Women who received anticoagulant therapy. Blood disorders (e.g. coagulopathies , thrombocytopenia). Consent Verbal and written consent were obtained from all eligible women . The candidate women were divided into two groups. A computer generated random numerical table was used by an independent statistician to prepare sealed opaque envelopes containing a group assignment. Two groups of envelopes, corresponding to two study groups, were given to a third party (a nurse), who was unaware of the contents. The nurse distributed envelopes to patients, alternating between the groups. Patientsassigned to group 1 received 5 IU oxytocin IV after delivery of the fetus+ 2 tabs placepo . Patients assigned to group 2 received 400 in the buccal space after anaesthesia + Iv saline infusion Procedure: Cesarean deliveries were performed by well- trained resident doctor supervised by Assistant lecturer or Obstetrician consultant. Cesarean section was performed under spinal anesthesia. Novasoconstrictor was used unless the blood pressure dropped by 20% fromthe baseline value; if this was the case, 10 mg ephedrine was given. Cesarean Delivery technique was the same in all recruited women. Abdominal skin incision was done through a Pfannenstiel incision 2 to 3cm above the symphysis pubis, with the mid portion of the incision within the shaved area of the pubic hair for a length of about 10-12cm was done. After the rectus fascia was opened, the rectus muscles were separated and dissected off the peritoneum which was picked up between two tissue forceps and opened longitudinally. The visceral peritoneum was dissected sharply and gently to separate the bladder from the uterus. The uterus was opened through a transverse lower segment incision. After clamping of the umbilical cord, the women received 1.5 gm Ampicillin -Sulbactam (Ultracillin, Sedico, Egypt) and 80 mg garamycin (Epigent, EPICO, EGYPT) Uterine repair by absorbable continuous vicryl 1 sutures in two layers , parietal peritoneum was sutured by absorbable continuous vicryl sutures, rectus sheath was closed by absorbable continuous vicryl 1. subcutaneous fatty layer was closed by absorbable continuous vicryl 0sutures, skin was closed by vicryl 2-0 by subcuticular sutures. All the towels were weighed before and after cesarean section and the difference were calculated, the amount of intraoperative blood loss was estimated in the suction apparatus in ml. A trained nurse was responsible for blood and amniotic fluid collection during surgery using two separate suction sets, as well as for weighing the surgical towels before and after surgery; all towels that were used were of the same size and weight and every 1 gm increase in weight was equated with 1-mLblood loss. The total amount of intra-operative blood loss was calculated.(blood loss in suction apparatus plus weight difference of used towels Second trained nurse was responsible for post-operative external blood loss measurement during the first 24 hours after surgery by weighing the soaked towels placed in the vulvar area. The post-operative blood loss was calculated (weight difference of towels placed in the vulvar area .The overall blood loss was calculated. Another blood picture was obtained 24 hours postoperative to detect changes in Hb level. The same nurse was responsible for follow up body temperature 2 hours after caesarean section (feverish if temperature is 38ºC or greater) and observation of the patient for nausea , vomiting , chills and diarrhea. Outcomes: Primary outcomes: involved estimation of intraoperative and postoperative blood loss for 24 hours ( blood loss estimation started immediately following the skin incision) Secondary outcomes: Changes in hemoglobin concentration ( hemoglobin concentrations were measured 2 hours before surgery and 24 hours after surgery) Misoprostol-induced maternal adverse effects (postoperativenausea, vomiting, diarrhea, fever and chills . Need to use other uterotonic drugs (oxytocin or ergometrine).Need to do further surgical interventions ( uterine artery ligation ,hysterectomy or re-exploration of the patient) Need for blood transfusion. Sample Size: Sample size was calculated based on the primary outcome (the amount of intraoperative blood loss during cs ) based on the results of previous study ,the mean blood loss with the use of Iv oxytocinas588.9ml with a standerd deviation of 96.3 ml (10). Assuming that buccal misoprostol is more effective in reducing blood loss by 10% 77 participants in each group will have 95% power at significance to detect such a 5% difference women were include in each group taking in account a 10% 77 drop-out rate (Epi-info: centers for disease control and prevention Atlanta, GA) Approval of Ethical Considerations: The Research Ethics Committee of Faculty of Medicine, Assiut University approved the study protocol. Pregnant women who would undergo elective lower segment cesarean section at term ( ≥ 37 weeks) with normal fetal heart tracing received written and verbal information about the study and were asked to participate. Those who agreed signed an informed consent form Statistical Analysis: Data entry and analysis were carried out using Statistical Package of Social Sciences for windows (SPSS, Chicago, Illinois, USA) version 20 Quantitative variables were presented in terms of mean± standard deviation and qualitative variables were expressed as frequency and percentage. Tests of significance (T-test and chi-square) were calculated Significance level was set at P value < 0.05.
Being tested
Misoprostol, Oxytocin
Medical subject headings
Postpartum Hemorrhage

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03676621
Study groupRoleWhat they receive
study groupExperimentalpatients will receive buccal misoprostol
Receives: Drug: Misoprostol
control groupActive comparatorpatients will receive intravenous oxytocin
Receives: Drug: Oxytocin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. mean blood loss

    the amount of blood in towels and suction drain

    Measured: 1 hour

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Sep 2018
  2. Study start1 Nov 2018
  3. Primary completion30 Aug 2021
  4. Study completion20 Sep 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
154 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03676621
Sponsor's protocol ID
BMISO
Status last verified
Sep 2021
First submitted
17 Sep 2018
Last updated
29 Sep 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Misoprostol and Oxytocin in people with Postpartum Hemorrhage, run by Assiut University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

mean blood loss (time frame: 1 hour). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in